Compare iShares Bitcoin Trust (IBIT) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Bitcoin Trust vs Mesoblast Limited — how do they compare? iShares Bitcoin Trust trades at $46.94 (market cap $67.31B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: iShares Bitcoin Trust is far larger — about 38.5× Mesoblast Limited's market cap, and iShares Bitcoin Trust is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 40 Days and Mesoblast Limited for 14 Days on average.
| IBIT | MESO | |
|---|---|---|
Market Cap | $67.31B | $1.75B |
Volume | 56,154,544 | 239,027 |
Sector | Crypto-linked | Health |
52-Week High | $68.74 | $20.96 |
52-Week Low | $33.29 | $13.19 |
Typical Hold Time | 40 Days | 14 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $47.21, down 2.64% on the day, with technical indicators showing a bullish overall signal. The stock faces immediate support at $47 and resistance at $48. Recent news highlights significant institutional interest, with BlackRock's IBIT recording $196 million in daily inflows according to 24/7 Wall Street on October 4, 2026.
The outlook remains positive with strong institutional inflows and technical momentum, though the absence of traditional financial metrics requires careful evaluation. Key risks include market volatility and dependency on Bitcoin ETF performance, while analyst sentiment appears cautiously optimistic based on recent fund flow trends.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
